---
title: "In the first half of the year, CIFI HOLD GP reported revenue of 12.28 billion yuan and a net loss of"
description: "In the first half of the year, CIFI HOLD GP reported revenue of 12.28 billion yuan and a net loss of 6.36 billion yuan"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/254143674.md"
published_at: "2025-08-22T10:27:41.000Z"
---

# In the first half of the year, CIFI HOLD GP reported revenue of 12.28 billion yuan and a net loss of

> In the first half of the year, CIFI HOLD GP reported revenue of 12.28 billion yuan and a net loss of 6.36 billion yuan

In the first half of the year, CIFI HOLD GP reported revenue of 12.28 billion yuan and a net loss of 6.36 billion yuan

### Related Stocks

- [00884.HK - CIFI HOLD GP](https://longbridge.com/en/quote/00884.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | [Link](https://longbridge.com/en/news/276024005.md) |
| Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | [Link](https://longbridge.com/en/news/276056763.md) |
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/en/news/276035104.md) |
| Shenhua Energy Gets Securities Regulator's Nod for Share Placement Plan | Shenhua Energy Gets Securities Regulator's Nod for Share Placement Plan | [Link](https://longbridge.com/en/news/275851575.md) |
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/en/news/276051793.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.